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Abstract:  Objective: The cardioprotective effects of activation of the A2A  adenosine receptor (A2AAR) on ischemia/ 
reperfusion injury in the heart remain controversial. We investigated whether ATL 313, a new selective A2AAR agonist, 
could reduce myocardial infarct size in a rat ischemia/reperfusion model.  
Methods: Sprague-Dawley rats were subjected to a 40 minute occlusion of the left coronary artery followed by 3 hours 
reperfusion. Hemodynamics were monitored during the procedure. The rats were divided into 3 groups: Group 1 received 
continuous intravenous infusion of saline given 10 min prior to ischemia and throughout reperfusion (n=8); Group 2  
received continuous intravenous infusion of 10 ng/kg/min of ATL 313 given 10 min prior to ischemia, and throughout 
reperfusion (n=8); and group 3 received an intravenous bolus of ATL 313 (900 ng/Kg body weight) given 10 min prior to 
ischemia, and continuous intravenous infusion of 10 ng/kg/min of ATL 313 started at 20 min after ischemia and through-
out reperfusion (n=8). After euthanasia of the rats, the hearts were harvested for the assessment of risk zone and zone of 
necrosis of the left ventricle.  
Results: The percentage of risk zone in the left ventricle was similar among group 1 (47 ± 3.7 %), group 2 (41.5 ± 4.2 %) 
and group 3 (42.4 ± 3.8 %). However, the infarct size, expressed as a percentage of the risk zone, was significantly  
decreased in group 3 (30.6 ± 5 %, P=0.01) compared with group 1 (53.8 ± 6.2 %) and group 2 (52.1 ± 4.8 %). In group 3, the 
bolus injection of ATL 313 caused a reduction in blood pressure during the procedure, and decreased heart rate and LV ±dp/ 
dt before coronary artery occlusion; but increased LV +dp/dt at the end of reperfusion compared to the other 2 groups.  
Conclusion: A2AAR agonist ATL313 significantly reduced infarct size and improved LV contractility at the end of reper-
fusion assessed by LV dp/dt at a dose of 900 ng/Kg. The mechanisms for the observed cardioprotection effect of ATL313 
remain to be determined.  
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INTRODUCTION 
  In the recent AMISTAD II post hoc analysis [1], patients 
receiving  adenosine  plus  early  coronary  artery  reperfusion 
had beneficial effects from the treatment including reduced 
death and smaller infarcts. Activation of adenosine receptors 
has been shown to reduce myocardial infarct size in experi-
mental models. Hale et al. [2] demonstrated that stimulation 
of adenosine receptors with an adenosine A1 receptor ago-
nist, R(-)-N-(2-phenylisopropyl)-adenosine (PIA), resulted in 
a significant reduction in myocardial infarct size in anaesthe-
tised rabbits that were subjected to 40 minutes of coronary 
artery  occlusion  followed  by  three  hours  of  reperfusion. 
Adenosine can signal through any of four types of G protein-
coupled  adenosine  receptors  (A1,  A2A,  A2B,  and  A3)  [3]. 
Whether activation of the A2A adenosine receptor (A2AAR) 
could  reduce  ischemia/reperfusion  injury  in  the  heart  re-
mains controversial. In one study, Lasley et al. [4] demon-
strated  that  intracoronary  infusions  of  the  A2AAR  agonist 
CGS-21680  reduced  myocardial  infarct  size  in  open-chest 
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pigs  that  were  subjected  to  60  minutes  of  coronary  artery 
occlusion  and  3  hours  of  reperfusion.  In  another  study, 
Glover  et  al.  [5]  reported  that  intravenous  infusion  of  the 
A2AAR agonist ATL-146e reduced myocardial infarct size in 
a canine model that was subjected to 90 minutes of coronary 
artery occlusion followed by 2 hours of reperfusion. How-
ever, some other studies have shown that A2AAR agonist has 
no  cardioprotective  effects  when  administered  prior  to  the 
onset of ischemia [6, 7]. 
  A  new  selective  A2AAR  agonist  4-{3-[6-amino-9-(5-
cyclopropylcarbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-
9H-purin-2-yl]prop- 2 -ynyl}piperidine-1-carboxylic  acid 
methyl ester (ATL 313) has been developed. ATL 313 is not 
metabolized in animals and has a longer half-life (30 min-
utes) compared to another A2AAR agonist, ATL-146e. Sev-
eral  studies  have  shown  that  ATL  313  attenuates  ische-
mia/reperfusion injury in the lung [8, 9]; however, the effect 
of ATL 313 on myocardial reperfusion injury has not been 
determined. This study was designed to investigate whether 
ATL 313 could reduce myocardial infarct size and favorably 
affect  left  ventricular  (LV)  function  in  a  rat  ischemia/ 
reperfusion model. ATL313 Reduces Myocardial Infarct Size in Rats  The Open Cardiovascular Medicine Journal, 2009, Volume 3    167 
METHODS 
  All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee, and performed in 
accordance with the “Guide for the Care and Use of Labora-
tory Animals” (NIH publication No. 85-23, National Acad-
emy Press, Washington DC, revised 1996). The Heart Insti-
tute at Good Samaritan Hospital is accredited by the Asso-
ciation  for  Assessment  and  Accreditation  of  Laboratory 
Animal Care International. 
ATL 313 Preparation 
  ATL 313 was made  as  concentrated stock solutions  in 
DMSO at a concentration of 100 µg/ml, and then diluted in 
phosphate-buffered saline (PBS; pH 7.4) to a concentration 
of 250 ng/ml.  
Animal Surgical Preparation 
  Female  Sprague-Dawley  (SD)  rats  (190~240g  body 
weight) were weighed and anesthetized with an intraperito-
neal administration of ketamine (7.5 mg/100 g body weight) 
and xylazine (0.5 mg/100 g body weight). Additional anes-
thesia was given throughout the study as required. The chest, 
neck  and  right  femoral  areas  were  shaved.  The  rats  were 
intubated and ventilated with room air (rate 60 cycles/min, 
tidal volume 1 ml per 100 g body weight), and placed on a 
heating pad (37 °C). The right carotid artery was exposed, 
and  a  2F  high-fidelity,  catheter-tipped  micromanometer 
(model SPR-869, Millar, Inc) was advanced into the ascend-
ing aorta and left ventricle (LV) to record LV hemodynamic 
parameters.  The  jugular vein  was  canulated  to inject ATL 
313 or vehicle,  and  to administer blue dye and potassium 
chloride at the end of the experiment. The femoral artery was 
isolated and catheterized to continuously monitor heart rate 
and arterial blood pressure using an ADI (Advanced Digital 
Instruments,  Grand  Junction,  CO)  system.  The  chest  was 
opened  through  the  4
th  intercostal  space.  The  pericardium 
was removed. The left coronary artery, which is located in 
the  groove  between  the  pulmonary  outflow  track  and  left 
ventricle, was encircled with 4-0 silk suture at the site just 
under the left atrium for occluding and reperfusing the ar-
tery. All of the rats were subjected to a 40 minutes coronary 
occlusion followed by 3 hours of reperfusion. At the end of 
the protocol, the coronary artery was reoccluded and 0.6ml 
50% Unisperse blue dye (Ciba Geigy, Hawthorne, NY) was 
injected  intravenously  to  delineate  the  risk  zone.  Animals 
were euthanized with 1 ml potassium chloride (149 mg/ml 
I.V.) under deep anesthesia, and the heart was excised. 
Experimental Groups 
  Animals were divided into 3 groups. Group 1 received 
continuous intravenous infusion of PBS given 10 min prior 
to ischemia and throughout reperfusion (n=8); Group 2 re-
ceived continuous intravenous infusion of 10 ng/kg/min of 
ATL 313 (dissolved in PBS) given 10 min prior to ischemia, 
and throughout reperfusion (n=8); and group 3 received an 
intravenous bolus of ATL 313 (900 ng/kg body weight; di-
luted in 0.6 ml PBS) given 10 min prior to ischemia, and 
continuous intravenous infusion of 10 ng/kg/min of ATL 313 
started at 20 min after ischemia and throughout reperfusion 
(n=8). The infusion rate of the pump was set at a rate of 7.9 
µl/min. During the 4 hours and 10 minutes of the procedure, 
a total volume of 1.98 ml was infused in all animals. 
Myocardial Risk Zone and Infarct Size Assessment  
  The left ventricle was cut into 4 equally thick transverse 
slices. These were photographed to show the ischemic risk 
zone (not stained blue, Fig. 1A). The slices were then incu-
bated in 1% triphenyltetrazolium chloride (TTC) for 15 min-
utes at 37 °C to delineate the necrotic zone (infarcted zone). 
TTC stains viable myocardial tissue brick red and infarcted 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Representative slices of heart from a rat in control group to show risk and necrosis area. A: Slices show the risk area. The area 
stained by blue dye represents the nonischemic area. The non-blue area (pink) is the ischemic risk zone. B: The same slices as in panel A 
stained for TTC. Brick red represents viable myocardial tissue and the white area is the necrotic tissue. Note the large homogeneous infarc-
tion (white area) of control ischemic myocardium. 168    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Dai et al. 
tissue appears white (Fig. 1B). The ventricular slices were 
then rephotographed. Projected photographs of the 3 slices 
below the coronary artery occlusion site in each heart, show-
ing the risk zone and the necrotic zone, were traced and then 
digitized using a computerized planimetric system. The areas 
of  ischemic  and  nonischemic  regions  were  computed  and 
expressed as a percentage of the slice, as were the percent-
ages of necrotic and non-necrotic tissue. The percentage in 
each slice was then multiplied by the weight of the slice to 
obtain mass. The masses were summed for each heart. Risk 
zone (unstained blue  zone) was expressed as a percentage  
of  the  left  ventricular  mass.  The  extent  of  necrosis  was  
calculated  as  percentage  of  the  left  ventricular  mass,  and  
the infarct size expressed as percentage of the ischemic risk 
zone (infarct size = extent of necrosis/extent of risk zone). 
Statistical Analysis 
  All data are reported as mean ± SEM. The risk zone and 
the infarct size, were compared by one-way ANOVA with 
subsequent Tukey’s post hoc test if appropriate. ANCOVA 
analysis was used for a group effect on the regression model 
of  risk  zone  versus  the  extent  of  necrosis.  Hemodynamic 
data were analyzed by repeated measures analysis of vari-
ance. If an over all significance of f < 0.05 was obtained, 
data among groups at specific time points were analyzed by 
ANOVA. Statistically significant differences are established 
at P<0.05. 
RESULTS 
Risk Zone, Zone of Necrosis and Infarct Size 
  The risk zone, which was expressed as the percentage of 
the left ventricular mass, was similar among group 1 (47 ± 
3.7 %), group 2 (41.5 ± 4.2 %) and group 3 (42.4 ± 3.8 %) 
(Fig. 2). However, infarct size, expressed as a percentage of 
the risk zone, was significantly decreased in group 3 (30.6 ± 
5 %, P=0.01) compared with group 1 (53.8 ± 6.2 %) and 
group 2 (52.1 ± 4.8 %) (Fig. 3). As shown in Fig. (4), the  
 
 
 
 
 
 
 
 
 
 
Fig. (2). Risk zone is expressed as percentage of LV mass. Risk zones are similar among the 3 groups. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Infarct size is expressed as percentage of the risk zone. The infarct size is significantly decreased in group 3 compared with the other 
two groups (p=0.01). ATL313 Reduces Myocardial Infarct Size in Rats  The Open Cardiovascular Medicine Journal, 2009, Volume 3    169 
extent of necrosis, which was expressed as the percentage of 
the left ventricular mass, was correlated with the risk size in 
each group (r was 0.92 in group 2 and group 3, and 0.79 in 
the  group  1),  and  the  regression  line  of  the  group  3  was 
shifted  downwards.  ANCOVA  analysis  demonstrated  that 
the group effect on the relationship was P<0.05. 
HEMODYNAMICS 
  As shown in Table 1, the injection of the bolus of ATL 
313 in group 3 significantly decreased arterial blood pressure 
during the procedure, suggesting that this dose of ATL 313 
caused  a  vasodilation  effect.  LV  ±dp/dt  was  significantly 
lower  in  group  3  compared  to  the  other  2  groups  before 
coronary  artery  occlusion.  However,  ATL  313  in  group  3 
significantly increased LV +dp/dt at the end of 3 hours of 
reperfusion. The heart rates were not significantly different 
among the  three groups prior to coronary artery occlusion 
(Table 1); but at this time point the heart rate was significant 
lower compared to the baseline in group 3 (p=0.016), sug-
gested ATL 313 decreased heart rate in group 3. 
DISCUSSION 
  The results of the present study indicated that the selec-
tive A2AAR agonist, ATL 313, reduced  myocardial infarct 
size and improved LV contractility at a dose with systemic 
hemodynamic  effects  in  a  rat  ischemia/reperfusion  model. 
However,  this  beneficial  effect  was  not  present  in  a  dose 
below  the  threshold  for  producing  systemic  hemodynamic 
effects. 
  A  number  of  studies  have  shown  that  A2AAR  agonists 
reduce infarct size in ischemic/reperfused myocardium. For 
example, Jordan et al. [10] demonstrated that intracoronary 
infusion of the selective A2AAR agonist CGS-21680 (started 
at  5  minutes  before  reperfusion  and  discontinued  after  
60  min)  significantly  reduced  infarction  in  anesthetized, 
open-chest  dogs  subjected  to  60  minutes  of  left  anterior  
descending coronary artery occlusion and 3 hr reperfusion. 
Glover  et  al.  [5]  observed  that  intravenous  infusion  of 
A2AAR agonist ATL-146e (begun at 5 minute before ische-
mia  and  continued  throughout  the  protocol  at  a  low, 
nonvasodilating dose) reduced infarct size in a canine model 
that was subjected to 90 minutes of coronary artery occlu-
sion followed by 2 hours of reperfusion. Yang et al. [11] also 
found that A2AAR activation by ATL 146e reduced infarct 
size in C57BL/6 mice after 45 minutes of left coronary artery 
occlusion followed by 24 hours of reperfusion. Smits et al. 
[12]  administered  adenosine  A1/A2  receptor  agonist  AMP 
579  before  ischemia  (bolus  loading  dose  i.v.  followed  by 
continuous i.v. infusion) in a porcine model of myocardial 
infarction  (40  minute  LAD  occlusion  followed  by  3  hour 
reperfusion).  AMP  579  significantly  reduced  infarct  size, 
and suggested that the cardioprotective effect of AMP 579 
was due to stimulation of adenosine A2 receptors. However, 
not all studies have shown a beneficial effect of A2AAR acti-
vation. Thornton et al. [6] reported that pretreatment with a 
selective  A2AAR  agonist  CGS  21680  (administered  at  15 
minutes before coronary occlusion) caused hypotension but 
failed  to  limit  myocardial  infarct  size  in  rabbits  that  were 
subjected to 30 minutes of regional coronary ischemia and 3 
hours of reperfusion. Lasley et al. [7] also demonstrated that 
preischemic  administration  of  the  A2AAR  agonist  CGS-
21680 did not reduce myocardial infarct size in rats submit-
ted  to  25  minutes  regional  myocardial  ischemia  and  2  h 
reperfusion. In our present study, A2AAR agonist ATL 313 
reduced infarct size in a dose with systemic hemodynamic 
effects in rat ischemia/reperfusion model. The difference in 
outcome between the present study and other studies may be 
due to the different A2AAR agonists utilized, different animal 
species or experimental protocol (particularly with regard to 
timing of administration and dosage). 
  The beneficial effects of treatment with A2AAR agonists 
may occur on the cardiac myocytes. A2AAR is also distrib-
uted in various cardiovascular tissue including atria, ventri-
 
 
 
 
 
 
 
 
 
 
Fig. (4). The association between myocardial risk zone (expressed as percentage of LV mass) and extent of necrosis (expressed as percentage 
of LV mass) in the 3 groups. Note that for any size risk zone, the extent of necrosis was smaller in group 3 compared with the other two 
groups. P<0.05 (group 3 vs. group 1 and 2) for group effect by ANCOVA. 170    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Dai et al. 
cle and coronary artery [13]. Activation of A2AAR can in-
crease inotropy of the ventricular myocytes [14] and/or im-
prove left ventricular function. Lasley et al. [4] found that 
low-dose  intracoronary  infusions  of  A2AAR  agonist  CGS-
21680 increased contractility in an in vivo stunned porcine 
myocardium  associated  with  a  small  decrease  in  arterial 
blood  pressure.  In  contrast,  Kilpatrick  et  al.  [15]  reported 
that treatment of isolated rat ventricular myocytes with the 
A2AAR agonist CGS-21680 failed to alter their contractility, 
although A2AAR were expressed  in  myocytes. Kilpatrick’s 
results are consistent with that of a lack of effect of CGS-
21680 in normal  intact myocardium [4].  These  conflicting 
results suggested that A2AAR activation may induce different 
effects on contractility in normal and stunned myocardium. 
Our  present  data  showed  that  ATL  313  significantly  de-
creased LV ±dp/dt initially before coronary artery occlusion 
(normal myocardium) in a dose with systemic hemodynamic 
effects, but significantly increased LV +dp/dt at the end of 3 
hours of reperfusion (injured myocardium), suggesting that 
ATL 313 improved LV contractility in reperfused myocar-
dium.  It  is  possible  that  during  ischemia  the  reduction  in 
afterload and contractility of the left ventricle reduced myo-
cardial oxygen demand, which then reduced myocardial in-
farct size. Upon reperfusion, the reduced infarct size coupled 
with enhanced contraction of the stunned myocardium may 
have explained the improved LV +dp/dt at the end of reper-
fusion. 
Table 1.  Hemodynamics (n=8 in Each Group) 
Baseline  Group 1  Group 2  Group 3  P value 
Heart rate (beats/minute)  242 ± 15   241 ± 9   235 ± 10   NS 
Systolic blood pressure (mmHg)  118 ± 5   117 ± 7   115 ± 9   NS 
Diastolic blood pressure (mmHg)  73 ± 5   80 ± 6   79 ± 5   NS 
Mean blood pressure (mmHg)  88 ± 5   92 ± 6   91 ± 6   NS 
+dp/dt (mmHg/second)  5281 ± 312   5732 ± 246   5482 ± 313   NS 
-dp/dt (mmHg/second)  4798 ± 262   5126 ± 275   4858 ± 303   NS 
    Prior to coronary artery occlusion 
Heart rate (beats/minute)  233 ± 16   212 ± 14   194 ± 9   NS 
Systolic blood pressure (mmHg)  132 ± 15   108 ± 7   68 ± 6   0.001* 
Diastolic blood pressure (mmHg)  76 ± 12   73 ± 7   35 ± 3   0.004* 
Mean blood pressure (mmHg)  95 ± 13   84 ± 7   46 ± 4   0.002* 
+dp/dt (mmHg/second)  5508 ± 454   5274 ± 300   3815 ± 376   0.01* 
-dp/dt (mmHg/second)  4938 ± 468   4492 ± 413   2660 ± 203   0.0008* 
    Prior to coronary artery reperfusion 
Heart rate (beats/minute)  221 ± 14   204 ± 10   203 ± 8   NS 
Systolic blood pressure (mmHg)  82 ± 4   77 ± 4   69 ± 5   NS 
Diastolic blood pressure (mmHg)  54 ± 4   43 ± 3   39 ± 3   0.012** 
Mean blood pressure (mmHg)  64 ± 4   54 ± 3   49 ± 4   0.018** 
+dp/dt (mmHg/second)  4069 ± 229   3684 ± 162   3898 ± 265   NS 
-dp/dt (mmHg/second)  2818 ± 154   2639 ± 345   2176 ± 120   NS 
     After 3 hour reperfusion 
Heart rate (beats/minute)  210 ± 14   211 ± 10   231 ± 8   NS 
Systolic blood pressure (mmHg)  78 ± 4   70 ± 3   71 ± 4   NS 
Diastolic blood pressure (mmHg)  48 ± 4   38 ± 2   37 ± 2   0.027** 
Mean blood pressure (mmHg)  58 ± 4   49 ± 2   48 ± 2   0.044** 
+dp/dt (mmHg/second)  3358 ± 99   3442 ± 182   4199 ± 207   0.0034* 
-dp/dt (mmHg/second)  2385 ± 125   2182 ± 154   2400 ± 229   NS 
NS=not significant difference; * significant difference (group 3 vs. other 2 groups); ** significance difference (group 3 vs. group 1). ATL313 Reduces Myocardial Infarct Size in Rats  The Open Cardiovascular Medicine Journal, 2009, Volume 3    171 
  Activation  of  A2AAR  in  cardiovascular  tissue  also  can 
cause vasorelaxation in coronary arteries [16]. Whether the 
cardioprotective effects of A2AAR activation are due to this 
vasorelaxation remains unknown. Glover et al. [5] showed 
that A2AAR agonist ATL-146e reduced infarct size without 
causing vasodilatation using very low, nonvasodilating doses 
in a canine model of reperfused myocardial infarction. Yang 
et  al.  [11]  also  found  that  ATL  146e  reduced  infarct  size 
after 45 minutes of left coronary artery occlusion followed 
by 24 hours of reperfusion at a dose that had no effect on 
heart rate, peripheral arterial pressure, or LV pressures in B6 
mice. These experimental studies all demonstrated that car-
dioprotection observed with A2AAR agonists  is not due  to 
direct  effect  on  the  vasculature.  However,  in  our  present 
study using the rat ischemia/reperfusion model, A2AAR ago-
nist ATL 313 did not reduce myocardial infarct size at a dose 
without vasodilating effects, although  it did reduce infarct 
size at a dose with vasodilating effects.  
  Our present study demonstrated that the reduction in in-
farct size observed in group 3 was associated with systemic 
hemodynamic effects. ATL 313 reduced blood pressure  to 
40% of the baseline value. While a  transient fall in blood 
pressure prior to coronary artery occlusion may result in a 
preconditioning  like  effect  [17],  the  fall  in  blood  pressure 
with the ATL 313 was not transient, but persistent – hence, it 
really did not mimic a transient preconditioning-like fall in 
blood  pressure.  In  addition,  several  studies  have  demon-
strated  that  systemic  hypotension  before  coronary  artery  
occlusion did not necessarily induce cardioprotection [6, 7]. 
Thornton et al. [6] and Lasley et al. [7] reported that pre-
treatment with a selective A2AAR agonist CGS 21680 before 
coronary  occlusion  caused  hypotension  but  failed  to  limit 
myocardial infarct size in rabbit and rat ischemia/reperfusion 
models. These data suggested that a decrease in blood pres-
sure before coronary artery occlusion may not be the sole 
cause of the beneficial effects of ATL 313 in our study. The 
systemic hypotension may be overcome by giving ATL 313 
into the coronary circulation to achieve a higher cardiac tis-
sue level instead of by intravenous injection. On the other 
hand a reduction in blood pressure during the ischemic event 
may benefit the heart by reducing oxygen demand (reduced 
afterload). 
  It  is  known  that  stimulation  of  A1AR  (A1  adenosine  
receptor)  results  in  a  negative  chronotropic  and  inotropic 
effect, while pure A2AAR activation inhibits neutrophil func-
tion and dilates vascular smooth muscle [6]. Thornton et al. 
[6] and Lasley et al. [7] have demonstrated the cardioprotec-
tion of stimulating A1AR by pretreatment with A1AR agonist 
before coronary occlusion in rabbit and rat model. Sun et al. 
[18] reported that the specificity of ATL313 for A2AAR was 
approximately  100-fold  greater  selectivity  compared  to 
A1AR  and  A3AR.  In  our  present  study,  ATL313  induced 
significant decrease in heart rate and LV dp/dt – suggested 
the dose of ATL313 was high enough to activate A1AR in 
group 3. Therefore, the cardioprotection of ATL313 in group 
3 may be due to  a preconditioning effect by activation of 
A1AR in a high dose with systemic hemodynamic  effects, 
and not by pure activation of A2AAR. 
  There are several  limitations in our present study. One 
limitation is that the bolus loading dose of ATL 313 induced 
profound hypotension in group 3, while hypotension during 
the acute course of myocardial infarction increases mortality 
in the clinical setting. Further studies are needed to investi-
gate whether  lower does of ATL 313, which  can  increase 
intracellular cyclic AMP but did not cause systemic hypoten-
sion, has  cardioprotective effects.  The second limitation is 
that bolus loading dose before ischemia plus continuous in-
travenous  infusion  was  used  in  group  3.  It  is  not  clear 
whether the observed cardioprotective effects are due to in-
creased  resistance  to  ischemia  or  anti-reperfusion  injury. 
Whether administration of ATL 313 starting before reperfu-
sion, which may be more clinically relevant, has cardiopro-
tective effects are needed. The third limitation is that we did 
not include a control group, with artificially reduced blood 
pressure, to allow differentiating cardioprotective effects of 
the  medication  versus  hemodynamic  effects.  Whether  hy-
potension alone induced the cardioprotective effects in the 
present study will require further investigation. 
  In  summary,  the  A2AAR  agonist  ATL313  significantly 
reduced infarct size and improved LV contractility at a dose 
with  systemic  hemodynamic  effects  in  a  rat  myocardial 
ischemia/reperfusion model. The mechanism of these bene-
ficial effects is not well understood. Whether cardioprotec-
tion by ATL313 is due to its actions on the vasculature, or 
through the preconditioning effect by stimulating A1AR, will 
require further investigation.  
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